FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Virol / Maturation of the cellular and humoral immune responses to p...
Journal of virology1997; 71(5); 3840-3852; doi: 10.1128/JVI.71.5.3840-3852.1997

Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process.

Abstract: Equine infectious anemia virus (EIAV) provides a natural model system by which immunological control of lentivirus infections may be studied. To date, no detailed study addressing in parallel both the humoral and cellular immune responses induced in horses upon infection by EIAV has been conducted. Therefore, we initiated the first comprehensive characterization of the cellular and humoral immune responses during clinical progression from chronic disease to inapparent stages of EIAV infection. Using new analyses of antibody avidity and antibody epitope conformation dependence that had not been previously employed in this system, we observed that the humoral immune response to EIAV required a 6- to 8-month period in which to fully mature. During this time frame, EIAV-specific antibody evolved gradually from a population characterized by low-avidity, nonneutralizing, and predominantly linear epitope specificity to an antibody population with an avidity of moderate to high levels, neutralizing activity, and predominantly conformational epitope specificity. Analyses of the cell-mediated immune response to EIAV revealed CD4+ and CD8+ major histocompatibility complex-restricted, EIAV-specific cytotoxic T-lymphocyte (CTL) activity apparent within 3 to 4 weeks postinfection, temporally correlating with the resolution of the primary viremia. After resolution of the initial viremia, EIAV-specific CTL activity differed greatly among the experimentally infected ponies, with some animals having readily detectable CTL activity while others had little measurable CTL activity. Thus, in contrast to the initial viremia, it appeared that no single immune parameter correlated with the resolution of further viremic episodes. Instead, immune control of EIAV infection during the clinically inapparent stage of infection appears to rely on a complex combination of immune system mechanisms to suppress viral replication that effectively functions only after the immune system has evolved to a fully mature state 6 to 8 months postinfection. These findings strongly imply the necessity for candidate EIAV and other lentivirus vaccines to achieve this immune system maturation for efficacious immunological control of lentivirus challenge.
Get Full Text
Publication Date: 1997-05-01 PubMed ID: 9094660PubMed Central: PMC191535DOI: 10.1128/JVI.71.5.3840-3852.1997Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't
  • Research Support
  • U.S. Gov't
  • P.H.S.

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research focuses on understanding the immune response evoked by equine infectious anemia virus (EIAV) in horses. It observes that a mature immune response, encompassing both cellular and humoral components, takes as long as 6-8 months to fully develop following EIAV infection and is vital for effective control of the virus.

Characterization of Cellular and Humoral Immune Responses

  • The study is the first in-depth investigation into the progression of both cellular and humoral immune responses in horses infected with EIAV.
  • Utilizing advancements in antibody avidity and epitope conformation dependence analyses, the research identifies a marked change in the humoral immune response over 6-8 months post-infection.
  • The initial low-avidity, nonneutralizing antibodies specific to linear epitopes evolve into moderate to high-avidity, neutralizing antibodies mainly targeting conformational epitopes.

Temporal Correlation with Viremia Resolution

  • Cell-mediated immune responses, including Major Histocompatibility Complex (MHC)-restricted CD4+ and CD8+ cytotoxic T-lymphocyte (CTL) activities against EIAV, are detected as early as 3 to 4 weeks post-infection, alongside the resolution of primary viremia.
  • However, the level of EIAV-specific CTL activity varies widely among horses following the resolution of initial viremia, hinting at the lack of a singular immune parameter responsible for the control of subsequent viremia episodes.

Immune System Maturation and Viral Control

  • Control of EIAV infection during the clinically inapparent stage seems to rely on a comprehensive combination of immune mechanisms working to suppress viral replication.
  • This control only becomes effective once the immune system has fully matured, which takes 6 to 8 months post-infection, underlining the necessity for potential EIAV vaccines to encourage this immune maturation for effective control of lentivirus.

Cite This Article

APA
Hammond SA, Cook SJ, Lichtenstein DL, Issel CJ, Montelaro RC. (1997). Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J Virol, 71(5), 3840-3852. https://doi.org/10.1128/JVI.71.5.3840-3852.1997

Publication

Journal of virology
ISSN: 0022-538X
NlmUniqueID: 0113724
Country: United States
Language: English
Volume: 71
Issue: 5
Pages: 3840-3852

Researcher Affiliations

Hammond, S A
  • Department of Molecular Genetics and Biochemistry, School of Medicine, University of Pittsburgh, Pennsylvania 15261, USA.
Cook, S J
    Lichtenstein, D L
      Issel, C J
        Montelaro, R C

          MeSH Terms

          • Animals
          • Antibodies, Viral / blood
          • Antibody Affinity
          • CD4-Positive T-Lymphocytes / immunology
          • Equine Infectious Anemia / immunology
          • Horses
          • Immunoglobulin G / blood
          • Lymphocyte Activation
          • Major Histocompatibility Complex
          • Protein Conformation
          • T-Lymphocytes, Cytotoxic / immunology

          Grant Funding

          • 5RO1 AI25810 / NIAID NIH HHS
          • 5T32 AI07487 / NIAID NIH HHS

          References

          This article includes 63 references
          1. Kono Y, Kobayashi K, Fukunaga Y. Immunization of horses against equine infectious anemia (EIA) with an attenuated EIA virus.. Natl Inst Anim Health Q (Tokyo) 1970 Fall;10(3):113-22.
            pubmed: 4320652
          2. Chakrabarti S, Brechling K, Moss B. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques.. Mol Cell Biol 1985 Dec;5(12):3403-9.
            pubmed: 3939316doi: 10.1128/mcb.5.12.3403-3409.1985google scholar: lookup
          3. Antczak DF, Bailey E, Barger B, Guerin G, Lazary S, McClure J, Mottironi VD, Symons R, Templeton J, Varewyck H. Joint report of the Third International Workshop on Lymphocyte Alloantigens of the Horse, Kennett Square, Pennsylvania, 25-27 April 1984.. Anim Genet 1986;17(4):363-73.
            pubmed: 3826760doi: 10.1111/j.1365-2052.1986.tb00730.xgoogle scholar: lookup
          4. Carpenter S, Evans LH, Sevoian M, Chesebro B. Role of the host immune response in selection of equine infectious anemia virus variants.. J Virol 1987 Dec;61(12):3783-9.
            pubmed: 2446008doi: 10.1128/JVI.61.12.3783-3789.1987google scholar: lookup
          5. O'Rourke K, Perryman LE, McGuire TC. Antiviral, anti-glycoprotein and neutralizing antibodies in foals with equine infectious anaemia virus.. J Gen Virol 1988 Mar;69 ( Pt 3):667-74.
            pubmed: 3351480doi: 10.1099/0022-1317-69-3-667google scholar: lookup
          6. Ball JM, Rao VS, Robey WG, Issel CJ, Montelaro RC. Lentivirus antigen purification and characterization: isolation of equine infectious anemia virus gag and env proteins in one step by reverse phase HPLC and application to human immunodeficiency virus glycoproteins.. J Virol Methods 1988 Mar-Apr;19(3-4):265-77.
            pubmed: 2836462doi: 10.1016/0166-0934(88)90021-3google scholar: lookup
          7. Perryman LE, O'Rourke KI, McGuire TC. Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection.. J Virol 1988 Aug;62(8):3073-6.
            pubmed: 2839723doi: 10.1128/JVI.62.8.3073-3076.1988google scholar: lookup
          8. Siliciano RF, Lawton T, Knall C, Karr RW, Berman P, Gregory T, Reinherz EL. Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion.. Cell 1988 Aug 12;54(4):561-75.
            pubmed: 2969774doi: 10.1016/0092-8674(88)90078-5google scholar: lookup
          9. Lew AM, Anders RF, Edwards SJ, Langford CJ. Comparison of antibody avidity and titre elicited by peptide as a protein conjugate or as expressed in vaccinia.. Immunology 1988 Oct;65(2):311-4.
            pubmed: 3056855
          10. Cianciolo GJ, Bogerd H, Snyderman R. Human retrovirus-related synthetic peptides inhibit T lymphocyte proliferation.. Immunol Lett 1988 Sep;19(1):7-13.
            pubmed: 2973436doi: 10.1016/0165-2478(88)90112-5google scholar: lookup
          11. Hedman K, Rousseau SA. Measurement of avidity of specific IgG for verification of recent primary rubella.. J Med Virol 1989 Apr;27(4):288-92.
            pubmed: 2723615doi: 10.1002/jmv.1890270406google scholar: lookup
          12. Hedman K, Hietala J, Tiilikainen A, Hartikainen-Sorri AL, Räihä K, Suni J, Väänänen P, Pietiläinen M. Maturation of immunoglobulin G avidity after rubella vaccination studied by an enzyme linked immunosorbent assay (avidity-ELISA) and by haemolysis typing.. J Med Virol 1989 Apr;27(4):293-8.
            pubmed: 2656909doi: 10.1002/jmv.1890270407google scholar: lookup
          13. Ruegg CL, Monell CR, Strand M. Inhibition of lymphoproliferation by a synthetic peptide with sequence identity to gp41 of human immunodeficiency virus type 1.. J Virol 1989 Aug;63(8):3257-60.
            pubmed: 2526228doi: 10.1128/JVI.63.8.3257-3260.1989google scholar: lookup
          14. Rwambo PM, Issel CJ, Adams WV Jr, Hussain KA, Miller M, Montelaro RC. Equine infectious anemia virus (EIAV) humoral responses of recipient ponies and antigenic variation during persistent infection.. Arch Virol 1990;111(3-4):199-212.
            pubmed: 2162160doi: 10.1007/BF01311054google scholar: lookup
          15. Rwambo PM, Issel CJ, Hussain KA, Montelaro RC. In vitro isolation of a neutralization escape mutant of equine infectious anemia virus (EIAV).. Arch Virol 1990;111(3-4):275-80.
            pubmed: 1693846doi: 10.1007/BF01311062google scholar: lookup
          16. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.. J Biol Chem 1990 Jun 25;265(18):10373-82.
            pubmed: 2355006
          17. Robinson JE, Holton D, Liu J, McMurdo H, Murciano A, Gohd R. A novel enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to HIV-1 envelope glycoproteins based on immobilization of viral glycoproteins in microtiter wells coated with concanavalin A.. J Immunol Methods 1990 Aug 28;132(1):63-71.
            pubmed: 2202766doi: 10.1016/0022-1759(90)90399-ggoogle scholar: lookup
          18. Kangro HO, Manzoor S, Harper DR. Antibody avidity following varicella-zoster virus infections.. J Med Virol 1991 Feb;33(2):100-5.
            pubmed: 1646852doi: 10.1002/jmv.1890330207google scholar: lookup
          19. Newman MJ, Issel CJ, Truax RE, Powell MD, Horohov DW, Montelaro RC. Transient suppression of equine immune responses by equine infectious anemia virus (EIAV).. Virology 1991 Sep;184(1):55-66.
            pubmed: 1651604doi: 10.1016/0042-6822(91)90821-rgoogle scholar: lookup
          20. Bailey E. Identification and genetics of horse lymphocyte alloantigens.. Immunogenetics 1980;11(5):499-506.
            pubmed: 6242885doi: 10.1007/BF01567818google scholar: lookup
          21. Gray D, Matzinger P. T cell memory is short-lived in the absence of antigen.. J Exp Med 1991 Nov 1;174(5):969-74.
            pubmed: 1834764doi: 10.1084/jem.174.5.969google scholar: lookup
          22. Salmi AA. Antibody affinity and protection in virus infections.. Curr Opin Immunol 1991 Aug;3(4):503-6.
            pubmed: 1755975doi: 10.1016/0952-7915(91)90011-ogoogle scholar: lookup
          23. Ball JM, Rushlow KE, Issel CJ, Montelaro RC. Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies.. J Virol 1992 Feb;66(2):732-42.
            pubmed: 1370556doi: 10.1128/JVI.66.2.732-742.1992google scholar: lookup
          24. Parekh BS, Pau CP, Granade TC, Rayfield M, De Cock KM, Gayle H, Schochetman G, George JR. Oligomeric nature of transmembrane glycoproteins of HIV-2: procedures for their efficient dissociation and preparation of Western blots for diagnosis.. AIDS 1991 Aug;5(8):1009-13.
            pubmed: 1777159
          25. Issel CJ, Horohov DW, Lea DF, Adams WV Jr, Hagius SD, McManus JM, Allison AC, Montelaro RC. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus.. J Virol 1992 Jun;66(6):3398-408.
            pubmed: 1316455doi: 10.1128/JVI.66.6.3398-3408.1992google scholar: lookup
          26. Sellon DC, Perry ST, Coggins L, Fuller FJ. Wild-type equine infectious anemia virus replicates in vivo predominantly in tissue macrophages, not in peripheral blood monocytes.. J Virol 1992 Oct;66(10):5906-13.
            pubmed: 1382143doi: 10.1128/JVI.66.10.5906-5913.1992google scholar: lookup
          27. Brown AR. Immunological functions of splenic B-lymphocytes.. Crit Rev Immunol 1992;11(6):395-417.
            pubmed: 1388711
          28. Oehen S, Waldner H, Kündig TM, Hengartner H, Zinkernagel RM. Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen.. J Exp Med 1992 Nov 1;176(5):1273-81.
            pubmed: 1402673doi: 10.1084/jem.176.5.1273google scholar: lookup
          29. Yewdell JW, Bennink JR. Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes.. Adv Immunol 1992;52:1-123.
            pubmed: 1442305doi: 10.1016/s0065-2776(08)60875-5google scholar: lookup
          30. Hammond SA, Bollinger RC, Tobery TW, Silliciano RF. Transporter-independent processing of HIV-1 envelope protein for recognition by CD8+ T cells.. Nature 1993 Jul 8;364(6433):158-61.
            pubmed: 8321286doi: 10.1038/364158a0google scholar: lookup
          31. Müllbacher A. The long-term maintenance of cytotoxic T cell memory does not require persistence of antigen.. J Exp Med 1994 Jan 1;179(1):317-21.
            pubmed: 8270876doi: 10.1084/jem.179.1.317google scholar: lookup
          32. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation.. Cell 1994 Jan 28;76(2):287-99.
            pubmed: 8293464doi: 10.1016/0092-8674(94)90336-0google scholar: lookup
          33. McGuire TC, Tumas DB, Byrne KM, Hines MT, Leib SR, Brassfield AL, O'Rourke KI, Perryman LE. Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins.. J Virol 1994 Mar;68(3):1459-67.
            pubmed: 8107209doi: 10.1128/JVI.68.3.1459-1467.1994google scholar: lookup
          34. Mascola JR, Mathieson BJ, Zack PM, Walker MC, Halstead SB, Burke DS. Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials.. AIDS Res Hum Retroviruses 1993 Dec;9(12):1175-84.
            pubmed: 7908211doi: 10.1089/aid.1993.9.1175google scholar: lookup
          35. Selin LK, Nahill SR, Welsh RM. Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses.. J Exp Med 1994 Jun 1;179(6):1933-43.
            pubmed: 8195718doi: 10.1084/jem.179.6.1933google scholar: lookup
          36. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.. J Virol 1994 Jul;68(7):4650-5.
            pubmed: 8207839doi: 10.1128/JVI.68.7.4650-4655.1994google scholar: lookup
          37. Lau LL, Jamieson BD, Somasundaram T, Ahmed R. Cytotoxic T-cell memory without antigen.. Nature 1994 Jun 23;369(6482):648-52.
            pubmed: 7516038doi: 10.1038/369648a0google scholar: lookup
          38. Moore JP, Cao Y, Ho DD, Koup RA. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.. J Virol 1994 Aug;68(8):5142-55.
            pubmed: 8035514doi: 10.1128/JVI.68.8.5142-5155.1994google scholar: lookup
          39. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.. J Virol 1994 Sep;68(9):6103-10.
            pubmed: 8057491doi: 10.1128/JVI.68.9.6103-6110.1994google scholar: lookup
          40. Sellon DC, Fuller FJ, McGuire TC. The immunopathogenesis of equine infectious anemia virus.. Virus Res 1994 May;32(2):111-38.
            pubmed: 8067050doi: 10.1016/0168-1702(94)90038-8google scholar: lookup
          41. Ward KN, Dhaliwal W, Ashworth KL, Clutterbuck EJ, Teo CG. Measurement of antibody avidity for hepatitis C virus distinguishes primary antibody responses from passively acquired antibody.. J Med Virol 1994 Aug;43(4):367-72.
            pubmed: 7525865doi: 10.1002/jmv.1890430409google scholar: lookup
          42. Allen G, Yeargan M, Costa LR, Cross R. Major histocompatibility complex class I-restricted cytotoxic T-lymphocyte responses in horses infected with equine herpesvirus 1.. J Virol 1995 Jan;69(1):606-12.
            pubmed: 7983765doi: 10.1128/JVI.69.1.606-612.1995google scholar: lookup
          43. Clements JE, Montelaro RC, Zink MC, Amedee AM, Miller S, Trichel AM, Jagerski B, Hauer D, Martin LN, Bohm RP. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.. J Virol 1995 May;69(5):2737-44.
            pubmed: 7707496doi: 10.1128/JVI.69.5.2737-2744.1995google scholar: lookup
          44. Lichtenstein DL, Rushlow KE, Cook RF, Raabe ML, Swardson CJ, Kociba GJ, Issel CJ, Montelaro RC. Replication in vitro and in vivo of an equine infectious anemia virus mutant deficient in dUTPase activity.. J Virol 1995 May;69(5):2881-8.
            pubmed: 7707512doi: 10.1128/JVI.69.5.2881-2888.1995google scholar: lookup
          45. Hammond SA, Johnson RP, Kalams SA, Walker BD, Takiguchi M, Safrit JT, Koup RA, Siliciano RF. An epitope-selective, transporter associated with antigen presentation (TAP)-1/2-independent pathway and a more general TAP-1/2-dependent antigen-processing pathway allow recognition of the HIV-1 envelope glycoprotein by CD8+ CTL.. J Immunol 1995 Jun 1;154(11):6140-56.
            pubmed: 7538543
          46. Rammensee HG. Chemistry of peptides associated with MHC class I and class II molecules.. Curr Opin Immunol 1995 Feb;7(1):85-96.
            pubmed: 7772286doi: 10.1016/0952-7915(95)80033-6google scholar: lookup
          47. Siliciano RF, Soloski MJ. MHC class I-restricted processing of transmembrane proteins. Mechanism and biologic significance.. J Immunol 1995 Jul 1;155(1):2-5.
            pubmed: 7602096
          48. Gardner M, Rosenthal A, Jennings M, Yee J, Antipa L, Robinson E Jr. Passive immunization of rhesus macaques against SIV infection and disease.. AIDS Res Hum Retroviruses 1995 Jul;11(7):843-54.
            pubmed: 7546912doi: 10.1089/aid.1995.11.843google scholar: lookup
          49. Ferris RL, Buck C, Hammond SA, Woods AS, Cotter RJ, Takiguchi M, Igarashi Y, Ichikawa Y, Siliciano RF. Class I-restricted presentation of an HIV-1 gp41 epitope containing an N-linked glycosylation site. Implications for the mechanism of processing of viral envelope proteins.. J Immunol 1996 Jan 15;156(2):834-40.
            pubmed: 8543840
          50. Zinkernagel RM. Immunology taught by viruses.. Science 1996 Jan 12;271(5246):173-8.
            pubmed: 8539616doi: 10.1126/science.271.5246.173google scholar: lookup
          51. Montelaro RC, Grund C, Raabe M, Woodson B, Cook RF, Cook S, Issel CJ. Characterization of protective and enhancing immune responses to equine infectious anemia virus resulting from experimental vaccines.. AIDS Res Hum Retroviruses 1996 Mar 20;12(5):413-5.
            pubmed: 8882322doi: 10.1089/aid.1996.12.413google scholar: lookup
          52. CRESTFIELD AM, MOORE S, STEIN WH. The preparation and enzymatic hydrolysis of reduced and S-carboxymethylated proteins.. J Biol Chem 1963 Feb;238:622-7.
            pubmed: 14023808
          53. Fujimiya Y, Perryman LE, Crawford TB. Leukocyte cytotoxicity in a persistent virus infection: presence of direct cytotoxicity but absence of antibody-dependent cellular cytotoxicity in horses infected with equine infectious anemia virus.. Infect Immun 1979 Jun;24(3):628-36.
            pubmed: 223981doi: 10.1128/iai.24.3.628-636.1979google scholar: lookup
          54. Gutekunst DE, Becvar CS. Responses in horses infected with equine infectious anemia virus adapted to tissue culture.. Am J Vet Res 1979 Jul;40(7):974-7.
            pubmed: 228570
          55. Issel CJ, Adams WV Jr, Meek L, Ochoa R. Transmission of equine infectious anemia virus from horses without clinical signs of disease.. J Am Vet Med Assoc 1982 Feb 1;180(3):272-5.
            pubmed: 6276353
          56. Orrego A, Issel CJ, Montelaro RC, Adams WV Jr. Virulence and in vitro growth of a cell-adapted strain of equine infectious anemia virus after serial passage in ponies.. Am J Vet Res 1982 Sep;43(9):1556-60.
            pubmed: 6293349
          57. Bailey E. Population studies on the ELA system in American standardbred and thoroughbred mares.. Anim Blood Groups Biochem Genet 1983;14(3):201-11.
            pubmed: 6660596doi: 10.1111/j.1365-2052.1983.tb01073.xgoogle scholar: lookup
          58. Issel CJ, Foil LD. Studies on equine infectious anemia virus transmission by insects.. J Am Vet Med Assoc 1984 Feb 1;184(3):293-7.
            pubmed: 6321420
          59. Montelaro RC, West M, Issel CJ. Antigenic reactivity of the major glycoprotein of equine infectious anemia virus, a retrovirus.. Virology 1984 Jul 30;136(2):368-74.
            pubmed: 6205503doi: 10.1016/0042-6822(84)90173-9google scholar: lookup
          60. Montelaro RC, Parekh B, Orrego A, Issel CJ. Antigenic variation during persistent infection by equine infectious anemia virus, a retrovirus.. J Biol Chem 1984 Aug 25;259(16):10539-44.
            pubmed: 6206055
          61. Siliciano RF, Keegan AD, Dintzis RZ, Dintzis HM, Shin HS. The interaction of nominal antigen with T cell antigen receptors. I. Specific binding of multivalent nominal antigen to cytolytic T cell clones.. J Immunol 1985 Aug;135(2):906-14.
            pubmed: 2409158
          62. Pullen GR, Fitzgerald MG, Hosking CS. Antibody avidity determination by ELISA using thiocyanate elution.. J Immunol Methods 1986 Jan 22;86(1):83-7.
            pubmed: 3944471doi: 10.1016/0022-1759(86)90268-1google scholar: lookup
          63. Kono Y, Kobayashi K, Fukunaga Y. Antigenic drift of equine infectious anemia virus in chronically infected horses.. Arch Gesamte Virusforsch 1973;41(1):1-10.
            pubmed: 4123810doi: 10.1007/BF01249923google scholar: lookup

          Citations

          This article has been cited 66 times.
          1. Hu Z, Guo K, Du C, Sun J, Naletoski I, Chu X, Lin Y, Wang X, Barrandeguy M, Samuel M, Wang W, Lau PI, Wernery U, Raghavan R, Wang X. Development and evaluation of a blocking ELISA for serological diagnosis of equine infectious anemia. Appl Microbiol Biotechnol 2023 May;107(10):3305-3317.
            doi: 10.1007/s00253-023-12504-5pubmed: 37039847google scholar: lookup
          2. Moharam I, Asala O, Reiche S, Hafez H, Beer M, Harder T, Grund C. Monoclonal antibodies specific for the hemagglutinin-neuraminidase protein define neutralizing epitopes specific for Newcastle disease virus genotype 2.VII from Egypt. Virol J 2021 Apr 26;18(1):86.
            doi: 10.1186/s12985-021-01540-0pubmed: 33902633google scholar: lookup
          3. Wong KA, Harker JA, Dolgoter A, Marooki N, Zuniga EI. T Cell-Intrinsic IL-6R Signaling Is Required for Optimal ICOS Expression and Viral Control during Chronic Infection. J Immunol 2019 Sep 15;203(6):1509-1520.
            doi: 10.4049/jimmunol.1801567pubmed: 31413107google scholar: lookup
          4. Bonckaert C, van der Meulen K, Rodríguez-Ballarà I, Pedrazuela Sanz R, Martinez MF, Nauwynck HJ. Modified-live PRRSV subtype 1 vaccine UNISTRAIN(®) PRRS provides a partial clinical and virological protection upon challenge with East European subtype 3 PRRSV strain Lena. Porcine Health Manag 2016;2:12.
            doi: 10.1186/s40813-016-0029-ypubmed: 28405438google scholar: lookup
          5. Cervantes DT, Ball JM, Edwards J, Payne S. Horses naturally infected with EIAV harbor 2 distinct SU populations but are monophyletic with respect to IN. Virus Genes 2016 Feb;52(1):71-80.
            doi: 10.1007/s11262-015-1280-zpubmed: 26739458google scholar: lookup
          6. Harker JA, Wong KA, Dolgoter A, Zuniga EI. Cell-Intrinsic gp130 Signaling on CD4+ T Cells Shapes Long-Lasting Antiviral Immunity. J Immunol 2015 Aug 1;195(3):1071-81.
            doi: 10.4049/jimmunol.1402402pubmed: 26085685google scholar: lookup
          7. Craigo JK, Ezzelarab C, Cook SJ, Liu C, Horohov D, Issel CJ, Montelaro RC. Protective efficacy of centralized and polyvalent envelope immunogens in an attenuated equine lentivirus vaccine. PLoS Pathog 2015 Jan;11(1):e1004610.
            doi: 10.1371/journal.ppat.1004610pubmed: 25569288google scholar: lookup
          8. Liu C, Cook SJ, Craigo JK, Cook FR, Issel CJ, Montelaro RC, Horohov DW. Epitope shifting of gp90-specific cellular immune responses in EIAV-infected ponies. Vet Immunol Immunopathol 2014 Oct 15;161(3-4):161-9.
            doi: 10.1016/j.vetimm.2014.08.001pubmed: 25176006google scholar: lookup
          9. Craigo JK, Montelaro RC. Lessons in AIDS vaccine development learned from studies of equine infectious, anemia virus infection and immunity. Viruses 2013 Dec 2;5(12):2963-76.
            doi: 10.3390/v5122963pubmed: 24316675google scholar: lookup
          10. Harker JA, Dolgoter A, Zuniga EI. Cell-intrinsic IL-27 and gp130 cytokine receptor signaling regulates virus-specific CD4⁺ T cell responses and viral control during chronic infection. Immunity 2013 Sep 19;39(3):548-59.
            doi: 10.1016/j.immuni.2013.08.010pubmed: 23993651google scholar: lookup
          11. Craigo JK, Ezzelarab C, Cook SJ, Chong L, Horohov D, Issel CJ, Montelaro RC. Envelope determinants of equine lentiviral vaccine protection. PLoS One 2013;8(6):e66093.
            doi: 10.1371/journal.pone.0066093pubmed: 23785473google scholar: lookup
          12. Meng Q, Lin Y, Ma J, Ma Y, Zhao L, Li S, Yang K, Zhou J, Shen R, Zhang X, Shao Y. A pilot study comparing the development of EIAV Env-specific antibodies induced by DNA/recombinant vaccinia-vectored vaccines and an attenuated Chinese EIAV vaccine. Viral Immunol 2012 Dec;25(6):477-84.
            doi: 10.1089/vim.2012.0014pubmed: 23171359google scholar: lookup
          13. Craigo JK, Ezzelarab C, Montelaro RC. Development of a high throughput, semi-automated, infectious center cell-based ELISA for equine infectious anemia virus. J Virol Methods 2012 Nov;185(2):221-7.
            doi: 10.1016/j.jviromet.2012.07.007pubmed: 22820072google scholar: lookup
          14. Liu C, Cook FR, Cook SJ, Craigo JK, Even DL, Issel CJ, Montelaro RC, Horohov DW. The determination of in vivo envelope-specific cell-mediated immune responses in equine infectious anemia virus-infected ponies. Vet Immunol Immunopathol 2012 Aug 15;148(3-4):302-10.
            doi: 10.1016/j.vetimm.2012.06.018pubmed: 22795699google scholar: lookup
          15. Harker JA, Lewis GM, Mack L, Zuniga EI. Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. Science 2011 Nov 11;334(6057):825-9.
            doi: 10.1126/science.1208421pubmed: 21960530google scholar: lookup
          16. Taylor SD, Leib SR, Wu W, Nelson R, Carpenter S, Mealey RH. Protective effects of broadly neutralizing immunoglobulin against homologous and heterologous equine infectious anemia virus infection in horses with severe combined immunodeficiency. J Virol 2011 Jul;85(13):6814-8.
            doi: 10.1128/JVI.00077-11pubmed: 21543497google scholar: lookup
          17. Craigo JK, Barnes S, Cook SJ, Issel CJ, Montelaro RC. Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from disease. Vaccine 2010 Nov 29;28(51):8095-104.
            doi: 10.1016/j.vaccine.2010.10.003pubmed: 20955830google scholar: lookup
          18. Liu L, Wan Y, Wu L, Sun J, Li H, Li H, Ma L, Shao Y. Broader HIV-1 neutralizing antibody responses induced by envelope glycoprotein mutants based on the EIAV attenuated vaccine. Retrovirology 2010 Sep 1;7:71.
            doi: 10.1186/1742-4690-7-71pubmed: 20807451google scholar: lookup
          19. Craigo JK, Barnes S, Zhang B, Cook SJ, Howe L, Issel CJ, Montelaro RC. An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family. Retrovirology 2009 Oct 20;6:95.
            doi: 10.1186/1742-4690-6-95pubmed: 19843328google scholar: lookup
          20. Mealey RH, Leib SR, Littke MH, Wagner B, Horohov DW, McGuire TC. Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen. Vaccine 2009 Apr 21;27(18):2453-68.
            doi: 10.1016/j.vaccine.2009.02.048pubmed: 19368787google scholar: lookup
          21. Zhang B, Montelaro RC. Replication of equine infectious anemia virus in engineered mouse NIH 3T3 cells. J Virol 2009 Feb;83(4):2034-7.
            doi: 10.1128/JVI.01883-08pubmed: 19073738google scholar: lookup
          22. McBurney SP, Ross TM. Viral sequence diversity: challenges for AIDS vaccine designs. Expert Rev Vaccines 2008 Nov;7(9):1405-17.
            doi: 10.1586/14760584.7.9.1405pubmed: 18980542google scholar: lookup
          23. Bogerd HP, Tallmadge RL, Oaks JL, Carpenter S, Cullen BR. Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism. J Virol 2008 Dec;82(23):11889-901.
            doi: 10.1128/JVI.01537-08pubmed: 18818324google scholar: lookup
          24. Tallmadge RL, Brindley MA, Salmans J, Mealey RH, Maury W, Carpenter S. Development and characterization of an equine infectious anemia virus Env-pseudotyped reporter virus. Clin Vaccine Immunol 2008 Jul;15(7):1138-40.
            doi: 10.1128/CVI.00088-08pubmed: 18448619google scholar: lookup
          25. Tagmyer TL, Craigo JK, Cook SJ, Even DL, Issel CJ, Montelaro RC. Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition. J Virol 2008 Apr;82(8):4052-63.
            doi: 10.1128/JVI.02028-07pubmed: 18234792google scholar: lookup
          26. Alvarez I, Gutierrez G, Ostlund E, Barrandeguy M, Trono K. Western blot assay using recombinant p26 antigen for detection of equine infectious anemia virus-specific antibodies. Clin Vaccine Immunol 2007 Dec;14(12):1646-8.
            doi: 10.1128/CVI.00293-07pubmed: 17959820google scholar: lookup
          27. Craigo JK, Zhang B, Barnes S, Tagmyer TL, Cook SJ, Issel CJ, Montelaro RC. Envelope variation as a primary determinant of lentiviral vaccine efficacy. Proc Natl Acad Sci U S A 2007 Sep 18;104(38):15105-10.
            doi: 10.1073/pnas.0706449104pubmed: 17846425google scholar: lookup
          28. Mealey RH, Littke MH, Leib SR, Davis WC, McGuire TC. Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals: lack of correlation between in vitro activity and in vivo efficacy. Vet Immunol Immunopathol 2008 Jan 15;121(1-2):8-22.
            doi: 10.1016/j.vetimm.2007.07.011pubmed: 17727961google scholar: lookup
          29. Mealey RH, Littke MH, Leib SR, Davis WC, McGuire TC. Cloning and large-scale expansion of epitope-specific equine cytotoxic T lymphocytes using an anti-equine CD3 monoclonal antibody and human recombinant IL-2. Vet Immunol Immunopathol 2007 Jul 15;118(1-2):121-8.
            doi: 10.1016/j.vetimm.2007.04.001pubmed: 17498813google scholar: lookup
          30. Steckbeck JD, Cole KS. Dissecting the humoral immune response to simian immunodeficiency virus: mechanisms of antibody-mediated virus neutralization. Immunol Res 2006;36(1-3):51-60.
            doi: 10.1385/IR:36:1:51pubmed: 17337766google scholar: lookup
          31. Mealey RH, Lee JH, Leib SR, Littke MH, McGuire TC. A single amino acid difference within the alpha-2 domain of two naturally occurring equine MHC class I molecules alters the recognition of Gag and Rev epitopes by equine infectious anemia virus-specific CTL. J Immunol 2006 Nov 15;177(10):7377-90.
            doi: 10.4049/jimmunol.177.10.7377pubmed: 17082657google scholar: lookup
          32. Craigo JK, Durkin S, Sturgeon TJ, Tagmyer T, Cook SJ, Issel CJ, Montelaro RC. Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines. Vaccine 2007 Jan 15;25(5):834-45.
            doi: 10.1016/j.vaccine.2006.09.040pubmed: 17023099google scholar: lookup
          33. Steckbeck JD, Grieser HJ, Sturgeon T, Taber R, Chow A, Bruno J, Murphy-Corb M, Montelaro RC, Cole KS. Dynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodeficiency virus identified by surface plasmon resonance. J Med Primatol 2006 Aug;35(4-5):248-60.
            doi: 10.1111/j.1600-0684.2006.00173.xpubmed: 16872288google scholar: lookup
          34. Mordasini F, Vogt HR, Zahno ML, Maeschli A, Nenci C, Zanoni R, Peterhans E, Bertoni G. Analysis of the antibody response to an immunodominant epitope of the envelope glycoprotein of a lentivirus and its diagnostic potential. J Clin Microbiol 2006 Mar;44(3):981-91.
            doi: 10.1128/JCM.44.3.981-991.2006pubmed: 16517887google scholar: lookup
          35. Jin S, Zhang B, Weisz OA, Montelaro RC. Receptor-mediated entry by equine infectious anemia virus utilizes a pH-dependent endocytic pathway. J Virol 2005 Dec;79(23):14489-97.
            doi: 10.1128/JVI.79.23.14489-14497.2005pubmed: 16282448google scholar: lookup
          36. Chung C, Mealey RH, McGuire TC. Evaluation of high functional avidity CTL to Gag epitope clusters in EIAV carrier horses. Virology 2005 Nov 25;342(2):228-39.
            doi: 10.1016/j.virol.2005.07.033pubmed: 16139857google scholar: lookup
          37. Fraser DG, Leib SR, Zhang BS, Mealey RH, Brown WC, McGuire TC. Lymphocyte proliferation responses induced to broadly reactive Th peptides did not protect against equine infectious anemia virus challenge. Clin Diagn Lab Immunol 2005 Aug;12(8):983-93.
            doi: 10.1128/CDLI.12.8.983-993.2005pubmed: 16085917google scholar: lookup
          38. Mealey RH, Sharif A, Ellis SA, Littke MH, Leib SR, McGuire TC. Early detection of dominant Env-specific and subdominant Gag-specific CD8+ lymphocytes in equine infectious anemia virus-infected horses using major histocompatibility complex class I/peptide tetrameric complexes. Virology 2005 Aug 15;339(1):110-26.
            doi: 10.1016/j.virol.2005.05.025pubmed: 15979679google scholar: lookup
          39. Craigo JK, Li F, Steckbeck JD, Durkin S, Howe L, Cook SJ, Issel C, Montelaro RC. Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy. J Virol 2005 Mar;79(5):2666-77.
            doi: 10.1128/JVI.79.5.2666-2677.2005pubmed: 15708986google scholar: lookup
          40. Chung C, Mealey RH, McGuire TC. CTL from EIAV carrier horses with diverse MHC class I alleles recognize epitope clusters in Gag matrix and capsid proteins. Virology 2004 Sep 15;327(1):144-54.
            doi: 10.1016/j.virol.2004.06.035pubmed: 15327905google scholar: lookup
          41. Payne SL, Pei XF, Jia B, Fagerness A, Fuller FJ. Influence of long terminal repeat and env on the virulence phenotype of equine infectious anemia virus. J Virol 2004 Mar;78(5):2478-85.
            doi: 10.1128/jvi.78.5.2478-2485.2004pubmed: 14963146google scholar: lookup
          42. Baccam P, Thompson RJ, Li Y, Sparks WO, Belshan M, Dorman KS, Wannemuehler Y, Oaks JL, Cornette JL, Carpenter S. Subpopulations of equine infectious anemia virus Rev coexist in vivo and differ in phenotype. J Virol 2003 Nov;77(22):12122-31.
            doi: 10.1128/jvi.77.22.12122-12131.2003pubmed: 14581549google scholar: lookup
          43. Mealey RH, Zhang B, Leib SR, Littke MH, McGuire TC. Epitope specificity is critical for high and moderate avidity cytotoxic T lymphocytes associated with control of viral load and clinical disease in horses with equine infectious anemia virus. Virology 2003 Sep 1;313(2):537-52.
            doi: 10.1016/s0042-6822(03)00344-1pubmed: 12954220google scholar: lookup
          44. Fraser DG, Mealey RH, McGuire TC. Selecting peptides to optimize Th1 responses to an equine lentivirus using HLA-DR binding motifs and defined HIV-1 Th peptides. Immunogenetics 2003 Oct;55(7):508-14.
            doi: 10.1007/s00251-003-0600-ypubmed: 12942208google scholar: lookup
          45. Li F, Craigo JK, Howe L, Steckbeck JD, Cook S, Issel C, Montelaro RC. A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. J Virol 2003 Jul;77(13):7244-53.
            doi: 10.1128/jvi.77.13.7244-7253.2003pubmed: 12805423google scholar: lookup
          46. Green TD, Montefiori DC, Ross TM. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J Virol 2003 Feb;77(3):2046-55.
            doi: 10.1128/jvi.77.3.2046-2055.2003pubmed: 12525639google scholar: lookup
          47. Howe L, Leroux C, Issel CJ, Montelaro RC. Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype. J Virol 2002 Nov;76(21):10588-97.
            doi: 10.1128/jvi.76.21.10588-10597.2002pubmed: 12368301google scholar: lookup
          48. Fraser DG, Oaks JL, Brown WC, McGuire TC. Identification of broadly recognized, T helper 1 lymphocyte epitopes in an equine lentivirus. Immunology 2002 Mar;105(3):295-305.
            doi: 10.1046/j.0019-2805.2001.01370.xpubmed: 11918691google scholar: lookup
          49. Ross TM, Xu Y, Green TD, Montefiori DC, Robinson HL. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res Hum Retroviruses 2001 Jun 10;17(9):829-35.
            doi: 10.1089/088922201750252025pubmed: 11429124google scholar: lookup
          50. Leroux C, Craigo JK, Issel CJ, Montelaro RC. Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies. J Virol 2001 May;75(10):4570-83.
            doi: 10.1128/JVI.75.10.4570-4583.2001pubmed: 11312327google scholar: lookup
          51. Ozyörük F, Cheevers WP, Hullinger GA, McGuire TC, Hutton M, Knowles DP. Monoclonal antibodies to conformational epitopes of the surface glycoprotein of caprine arthritis-encephalitis virus: potential application to competitive-inhibition enzyme-linked immunosorbent assay for detecting antibodies in goat sera. Clin Diagn Lab Immunol 2001 Jan;8(1):44-51.
            doi: 10.1128/CDLI.8.1.44-51.2001pubmed: 11139194google scholar: lookup
          52. Hammond SA, Li F, McKeon BM Sr, Cook SJ, Issel CJ, Montelaro RC. Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus. J Virol 2000 Jul;74(13):5968-81.
            doi: 10.1128/jvi.74.13.5968-5981.2000pubmed: 10846078google scholar: lookup
          53. Tencza SB, Islam KR, Kalia V, Nasir MS, Jolley ME, Montelaro RC. Development of a fluorescence polarization-based diagnostic assay for equine infectious anemia virus. J Clin Microbiol 2000 May;38(5):1854-9.
            doi: 10.1128/JCM.38.5.1854-1859.2000pubmed: 10790112google scholar: lookup
          54. Harrold SM, Cook SJ, Cook RF, Rushlow KE, Issel CJ, Montelaro RC. Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids. J Virol 2000 Apr;74(7):3112-21.
            doi: 10.1128/jvi.74.7.3112-3121.2000pubmed: 10708426google scholar: lookup
          55. Kaikkonen L, Lankinen H, Harjunpää I, Hokynar K, Söderlund-Venermo M, Oker-Blom C, Hedman L, Hedman K. Acute-phase-specific heptapeptide epitope for diagnosis of parvovirus B19 infection. J Clin Microbiol 1999 Dec;37(12):3952-6.
            doi: 10.1128/JCM.37.12.3952-3956.1999pubmed: 10565913google scholar: lookup
          56. Lonning SM, Zhang W, Leib SR, McGuire TC. Detection and induction of equine infectious anemia virus-specific cytotoxic T-lymphocyte responses by use of recombinant retroviral vectors. J Virol 1999 Apr;73(4):2762-9.
            doi: 10.1128/JVI.73.4.2762-2769.1999pubmed: 10074123google scholar: lookup
          57. Mazzetti P, Giannecchini S, Del Mauro D, Matteucci D, Portincasa P, Merico A, Chezzi C, Bendinelli M. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine. J Virol 1999 Jan;73(1):1-10.
            doi: 10.1128/JVI.73.1.1-10.1999pubmed: 9847300google scholar: lookup
          58. Zhang W, Lonning SM, McGuire TC. Gag protein epitopes recognized by ELA-A-restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus infection. J Virol 1998 Dec;72(12):9612-20.
            doi: 10.1128/JVI.72.12.9612-9620.1998pubmed: 9811694google scholar: lookup
          59. Richmond JF, Lu S, Santoro JC, Weng J, Hu SL, Montefiori DC, Robinson HL. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol 1998 Nov;72(11):9092-100.
            doi: 10.1128/JVI.72.11.9092-9100.1998pubmed: 9765454google scholar: lookup
          60. Cole KS, Murphey-Corb M, Narayan O, Joag SV, Shaw GM, Montelaro RC. Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections. J Virol 1998 Oct;72(10):7852-9.
            doi: 10.1128/JVI.72.10.7852-7859.1998pubmed: 9733822google scholar: lookup
          61. Oaks JL, McGuire TC, Ulibarri C, Crawford TB. Equine infectious anemia virus is found in tissue macrophages during subclinical infection. J Virol 1998 Sep;72(9):7263-9.
            doi: 10.1128/JVI.72.9.7263-7269.1998pubmed: 9696821google scholar: lookup
          62. Harmache A, Vitu C, Guiguen F, Russo P, Bertoni G, Pepin M, Vigne R, Suzan M. Priming with tat-deleted caprine arthritis encephalitis virus (CAEV) proviral DNA or live virus protects goats from challenge with pathogenic CAEV. J Virol 1998 Aug;72(8):6796-804.
            doi: 10.1128/JVI.72.8.6796-6804.1998pubmed: 9658128google scholar: lookup
          63. Belshan M, Harris ME, Shoemaker AE, Hope TJ, Carpenter S. Biological characterization of Rev variation in equine infectious anemia virus. J Virol 1998 May;72(5):4421-6.
            doi: 10.1128/JVI.72.5.4421-4426.1998pubmed: 9557734google scholar: lookup
          64. Cook RF, Leroux C, Cook SJ, Berger SL, Lichtenstein DL, Ghabrial NN, Montelaro RC, Issel CJ. Development and characterization of an in vivo pathogenic molecular clone of equine infectious anemia virus. J Virol 1998 Feb;72(2):1383-93.
            doi: 10.1128/JVI.72.2.1383-1393.1998pubmed: 9445039google scholar: lookup
          65. Leroux C, Issel CJ, Montelaro RC. Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony. J Virol 1997 Dec;71(12):9627-39.
            doi: 10.1128/JVI.71.12.9627-9639.1997pubmed: 9371627google scholar: lookup
          66. Cole KS, Rowles JL, Jagerski BA, Murphey-Corb M, Unangst T, Clements JE, Robinson J, Wyand MS, Desrosiers RC, Montelaro RC. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J Virol 1997 Jul;71(7):5069-79.
            doi: 10.1128/JVI.71.7.5069-5079.1997pubmed: 9188572google scholar: lookup
          Subscribe to our newsletter
          Join 99,001 horse owners like you who receive our email updates on horse health and nutrition.